View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
March 31, 2021updated 12 Jul 2022 11:21am

ARN launches new patient centric unit for rheumatology trials

American Rheumatology Network (ARN) has launched ARN Clinical Research, a patient centric and real-world technology unit for transforming rheumatology trials and care.

American Rheumatology Network (ARN) has launched ARN Clinical Research, a patient centric and real-world technology unit for transforming rheumatology trials and care.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The new unit will be dedicated to transforming drug development efforts in rheumatology research in collaboration with real-world technology solutions provider Trio Health.

ARN Clinical Research will bring together the power of the ARN network with Trio’s data management technologies to develop an integrated clinical research ecosystem.

Through this ecosystem, manufactures will be able to achieve their goals for delivering patient-centric treatment approaches that would be in line with existing unmet needs.

ARN CEO Michael Cooper said: “The launch of this dedicated unit builds on ARN’s long standing commitment and history in community rheumatology and clinical research.

“By tapping into the largest rheumatology network in the US, ARN Clinical Research has amassed a set of game-changing capabilities to support manufacturers’ drug development efforts in the fight to transform rheumatologic diseases.”

ARN Clinical Research has direct connection to the rheumatology practices integrated through its MDX Platform that gives manufactures access to more than 35 physician practices and real-time patient experiences.

Manufacturers will get a clear view for the patient symptomatic therapy to support clinical strategy and clinical trial execution for introducing new and targeted treatment options with different mechanisms of action to patients.

The centralised ARN Clinical Research unit is better equipped to deploy new clinical research models including decentralised and hybrid trials, pragmatic trials, and synthetic arms.

The services delivered by ARN Clinical Research will support the complete product lifecycle, including physician advisory boards, rapid start up for clinical trials, patient recruitment, and data management.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena